Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) has been an alternative source of stem cell transplantation,the successful application of which makes each transplant candidate has his/her donor.In this paper,advances in the Haplo-HSCT reported in the 56th American Society of Hematology (ASH) annual meeting are reviewed.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curable method for hematological malignancies.Nearly all transplant candidates have donor with the successful application of haploidentical SCT.This article summarized some reports on donor selection,prophylaxis and treatment of graft-versus-host disease,and graft failure in the 58th American Society of Hematology Annual Meeting to present the progress of allo-HSCT in treating hematological malignancies.

Allo-HSCT is a potentially curative therapy for many hematological malignancies,the basis of which is graft-versus-leukemia(GVL) effect.However,acute graft-versus-host disease(GVHD) is responsible for 15% to 40% of mortality and is the major cause of morbidity after transplantation.Therefore,separation of GVHD and GVL partially or completely could improve the transplant outcomes.This study focuses on the effects of G-CSF on T cells in peripheral blood stem cell grafts and bone marrow grafts and its mechanisms after in vivo G-CSF application.The separation of GVHD and GVL effect and the mechanisms of which after in vivo G-CSF and interleukin-11(IL-11) treatment of healthy donors were investigated.The main contributions of this research are listed as follows:(1) Immune tolerance of T cells was induced simultaneously in peripheral blood stem cell grafts and bone marrow grafts after in vivo G-CSF application;(2) T cell hyporesponsiveness and polarization of T cells from Th1 to Th2 were maintained after mixture of G-CSF-mobilized peripheral blood grafts(G-PB) and G-CSF-primed bone marrow grafts(G-BM) according to different proportions in vitro;(3) Treating donor with G-CSF and IL-11 decreased GVHD and retained GVL effect;(4) The incidence of acute GVHD was decreased after Allo-HSCT using G-PB and G-BM as allografts;(5) In combination with other techniques,the HLA barriers were overcomed using G-PB and G-BM as allografts;(6) The incidences of acute GVHD were significantly decreased and the GVL effects were retained or enhanced in relapsed patients after treatment by G-CSF-mobilized peripheral blood graft infusion compared with those received steady-state peripheral blood lymphocyte infusion,indicating that GVHD and GVL could be partially separated in clinical settings.Based on our results,we would conclude that the issues on the deficiency of donors are resolved,and novel strategies offered for the prophylaxis and treatment of patients with hematological malignancies who relapse after Allo-HSCT.Further studies on the mechanism of the separation of GVL and GVHD are warranted.

Minimal residual disease (MRD) is one of the important variables to evaluate the outcomes of patients with leukemia, which is related to the relapse and survival of patients after treatment. This article summarizes the new progress on diagnosis and treatment of leukemia from the perspective of MRD in combination with some representative studies on MRD-based prognostic assessment and guidance on treatment options that were reported at the 62nd American Society of Hematology (ASH) Annual Meeting.

Objective To explore the immunologic composition and T cell function of rhG-CSF mobilized peripheral blood grafts(G-PB) and rhG-CSF primed bone marrow grafts(G-BM) after being mixed in different proportions.Methods T cell subgroups,dendritic cells(DC) and its subsets in G-PB and G-BM were analyzed by multicolor flow cytometry.Immunologic composition of G-PB and G-BM after mixture in different proportions were calculated,lymphocyte proliferation ability and quantities of interleukin-4(IL-4),interferon-?(IFN-?) secretion by T cells in mixture grafts were determined using MTT and sandwich ELISA assays.Results After co-incubation of G-PB with G-BM in different proportions,T cell proliferation in mixture grafts was lower than that of NG-BM and G-PB(P

Objective To explore the difference of immunological characteristics between recombination human granulocyte colony-stimulating factor(rhG-CSF)mobilized peripheral blood grafts(G-PB)and steady-state bone marrow grafts(SS-BM).Methods From April to October 2003,G-PB and SS-BM of 15 related donors were collected.T cell subgroups,dendritic cells(DC),monocytes and the expression of CD28 costimulatory molecules on T cells were determined by multicolor flow cytometry.The lymphocyte proliferation ability and the quantities of interleukin-4(IL-4)and interferon-?(IFN-?)secreted by T cells were determined using MTT assays and sandwich ELISA.Results The absolute numbers of monocytes,CD3+,CD4+ and CD8+ T cells,and the ratios of CD4/CD8 in G-PB were significantly higher than those in SS-BM,respectively(P0.05).The quantities of IFN-? and IL-4 secreted by T cells per micromilter in G-PB was significantly higher than those in SS-BM(P0.05).The absolute numbers of DC1 and DC2 in G-PB were significantly higher than those in SS-BM(P0.05).Conclusion It is concluded that the difference of immunological characteristics between G-PB and SS-BM may explain the lower incidence of GVHD and lower relapse rate after SS-BM and G-PB transplantation.

Objective To investigate the correlation of monocyte counts prior to the collection of recombinant human granulocyte colony-stimulating factor(rhG-CSF)primed bone marrow grafts(G-BM)with the quantities of CD34+ cells in the grafts.Methods From June 2004 to July 2007,fifty-three healthy donors were treated with rhG-CSF[5 ?g/(kg?d)]injected subcutaneously for five consecutive days.Bone marrow grafts and peripheral blood grafts were harvested on the 4th and 5th day,respectively.The quantities of CD34+ cells and blood routine prior to the collection of the G-BM were determined by flow cytometry and blood analyzer XL2100,respectively.Results The monocyte counts in peripheral blood(PB)of the 53 healthy donors were 896?424 per microliter.The counts of CD34+ cells per microliter and quantities of total CD34+ cells in the bone marrow grafts were 84?45 and(8.22?4.84)?107,respectively.Pearson correlation analysis indicated that the counts of monocyte in the PB correlated positively with the counts of CD34+ cells per microliter(r=0.573,P

theengraftment of neutrophil and platelet after HLA-matched sibling allogeneic blood and marrow transplantation.Duration from diagnosis to trarmplantation was another factor influencing engraftment of platelet.

The development and progression of liver cancer have the stages of hepatitis, liver cirrhosis, precancerous lesion, and liver cancer, among which the malignant transformation of precancerous lesions of liver cancer is closely associated with the activation of hepatic stellate cells (HSC). By describing the activation of HSC, the generation of precancerous cells of liver cancer, the formation of inflammatory fibrotic microenvironment, and the association between HSC activation and precancerous lesion, this article points out that microRNAs can affect the malignant transformation of precancerous lesion of liver cancer by regulating the expression of related target genes and HSC activation, and the research in this field is expected to provide new ideas and targets for the prevention and treatment of liver cancer.

Proteomics is one of the most advanced fields and hotspots in the research of various diseases in recent years. Its development has provided a new research direction for the early diagnosis and treatment of diabetes and has achieved some research results. Early diagnosis is helpful to control the progression of the disease or even avoid surgical treatment, which is of great significance for improving the prognosis of patients. This paper reviews the current status and prospects of proteomic technology and its applications in diabetes as well as its complications with a prospect of the impact of the rapid development of proteomics on diabetes and its positive role in discovering more diabetes biomarkers. In the future research, more attention should be paid to the interconnections between biomarkers.